688180 君实生物
已收盘 07-22 15:00:00
资讯
新帖
简况
国产创新药板块里程碑进展频现,创新药ETF(159992)跟踪指数逆市上涨,浙江医药、君实生物-U、特宝生物领涨。
和讯网 · 07-18
国产创新药板块里程碑进展频现,创新药ETF(159992)跟踪指数逆市上涨,浙江医药、君实生物-U、特宝生物领涨。
港股异动 | 君实生物(01877)涨超4% 特瑞普利单抗新适应症上市申请获受理
智通财经网 · 07-18
港股异动 | 君实生物(01877)涨超4% 特瑞普利单抗新适应症上市申请获受理
精准医疗概念盘中拉升,君实生物-U涨1.48%
自选股智能写手 · 07-18
精准医疗概念盘中拉升,君实生物-U涨1.48%
独家药品概念盘中拉升,君实生物-U涨1.48%
自选股智能写手 · 07-18
独家药品概念盘中拉升,君实生物-U涨1.48%
君实生物(01877.HK)特瑞普利单抗新适应症上市申请获受理
阿斯达克财经 · 07-18
君实生物(01877.HK)特瑞普利单抗新适应症上市申请获受理
君实生物(01877):特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理
智通财经 · 07-17
君实生物(01877):特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理
君实生物:特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理
国际金融报 · 07-17
君实生物:特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理
君实生物(01877)下跌5.13%,报12.58元/股
金融界 · 07-16
君实生物(01877)下跌5.13%,报12.58元/股
君实生物盘中异动 下午盘快速跳水5.13%
自选股智能写手 · 07-16
君实生物盘中异动 下午盘快速跳水5.13%
君实生物(01877)上涨5.13%,报13.12元/股
金融界 · 07-11
君实生物(01877)上涨5.13%,报13.12元/股
君实生物盘中异动 急速上涨5.12%
自选股智能写手 · 07-11
君实生物盘中异动 急速上涨5.12%
君实生物(01877)股价上升5.128%,现价港币$13.12
阿斯达克财经 · 07-11
君实生物(01877)股价上升5.128%,现价港币$13.12
君实生物-U创3月新高 11家券商给予买入建议
智选洞察 · 07-11
君实生物-U创3月新高 11家券商给予买入建议
君实生物(01877)全资子公司苏州众合生物医药科技通过欧盟 GMP 认证
智通财经 · 07-10
君实生物(01877)全资子公司苏州众合生物医药科技通过欧盟 GMP 认证
君实生物(688180.SH):子公司通过欧盟GMP认证
智通财经 · 07-10
君实生物(688180.SH):子公司通过欧盟GMP认证
君实生物(01877.HK)WJ47156片临床试验申请获受理
阿斯达克财经 · 07-10
君实生物(01877.HK)WJ47156片临床试验申请获受理
君实生物(01877):JS125 获得药物临床试验申请受理通知书
智通财经 · 07-09
君实生物(01877):JS125 获得药物临床试验申请受理通知书
概念掘金 | 创新药重磅政策落地!多主线投资机会显现
格隆汇 · 07-08
概念掘金 | 创新药重磅政策落地!多主线投资机会显现
君实生物获得发明专利授权:“抗PD-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法”
证券之星 · 07-06
君实生物获得发明专利授权:“抗PD-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法”
君实生物(01877)上涨5.3%,报12.32元/股
金融界 · 07-05
君实生物(01877)上涨5.3%,报12.32元/股
公司概况
公司名称:
上海君实生物医药科技股份有限公司
所属行业:
医药制造业
上市日期:
2020-07-15
主营业务:
上海君实生物医药科技股份有限公司主营业务为新药的研发及相关技术的转让和服务,新药的生产和销售,其主要产品与服务项目单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术转让等。公司提供的技术服务指利用技术平台为客户提供定制服务,包括分子序列的设计及改造、高表达细胞株的构建、小试及中试工艺研究、临床前研究及临床研究样品的制备等。公司为第一家获得NMPA的抗PD-1单克隆抗体上市批准的中国公司。国内首个获批临床的抗PCSK9单抗、全球首个获批临床的抗BTLA单抗和首个在欧美等海外国家及地区获得紧急使用授权(EUA)的国产COVID-19治疗药物埃特司韦单抗。
发行价格:
55.50
{"stockData":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":32,"timestamp":1721631600000,"preClose":31.69,"halted":0,"volume":3346069,"delay":0,"floatShares":765000000,"shares":986000000,"eps":-2.0524,"marketStatus":"已收盘","marketStatusCode":5,"change":0.31,"latestTime":"07-22 15:00:00","open":31.47,"high":32.28,"low":31.33,"amount":107000000,"amplitude":0.03,"askPrice":32,"askSize":2,"bidPrice":31.98,"bidSize":4,"shortable":0,"etf":0,"ttmEps":-2.0524,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":31.69,"symbolType":"stock_kcb","openAndCloseTimeList":[[1721611800000,1721619000000],[1721624400000,1721631600000]],"highLimit":34.86,"lowLimit":28.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":985689871,"pbRate":4.59,"roa":"--","roe":"--","epsLYR":-2.32,"committee":-0.549669,"marketValue":31542000000,"floatMarketCap":24466000000,"peRate":-15.591502,"changeRate":0.0098,"turnoverRate":0.0044,"status":0,"afterMarket":{"amount":0,"volume":0,"close":32,"buyVolume":0,"sellVolume":0,"time":1721633637153,"indexStatus":"已收盘 07-22 15:30:00","preClose":31.69}},"requestUrl":"/m/hq/s/688180/wiki","defaultTab":"wiki","newsList":[{"id":"2452220125","title":"国产创新药板块里程碑进展频现,创新药ETF(159992)跟踪指数逆市上涨,浙江医药、君实生物-U、特宝生物领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2452220125","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452220125?lang=zh_cn&edition=full","pubTime":"2024-07-18 11:03","pubTimestamp":1721271813,"startTime":"0","endTime":"0","summary":"2024年7月18日,创新药板块逆市大涨。盘面上,浙江医药领涨,君实生物-U、特宝生物跟涨,创新药ETF市场热度较高,过去5个交易日日均成交额2.24亿元。西南证券表示,重要产品的里程碑进展和临床数据披露是股价的重要催化剂。下半年,A股多家药企将有众多里程碑进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071812461895d3120c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071812461895d3120c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0028","688180","600216","688278","BK0188","BK0191","515120","159992"],"gpt_icon":0},{"id":"2452149806","title":"港股异动 | 君实生物(01877)涨超4% 特瑞普利单抗新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452149806","media":"智通财经网","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452149806?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:57","pubTimestamp":1721267862,"startTime":"0","endTime":"0","summary":"消息面上,君实生物公布,近日,公司收到国家药监局核准签发的《受理通知书》,特瑞普利单抗联合贝伐珠单抗用于不可切除或转移性肝细胞癌患者的一线治疗的新适应症上市申请获得受理。这是特瑞普利单抗在中国内地递交的第十一项上市申请。天风证券此前指出,公司营业收入增长主要来自商业化药品销售收入的增长,其中核心产品特瑞普利单抗贡献突出。2023 年,特瑞普利单抗销售收入9.19 亿元,同比增长约24.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1515","YANG","BK1583","BK0239","HSTECH","688180","BK1161","01877","HSCEI"],"gpt_icon":1},{"id":"2452453251","title":"精准医疗概念盘中拉升,君实生物-U涨1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452453251","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452453251?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:40","pubTimestamp":1721266859,"startTime":"0","endTime":"0","summary":"07月18日,精准医疗概念盘中拉升,截至09点40分,精准医疗概念整体指数上涨0.54%,报642.320点。从个股上来看,该概念的成分股中,君实生物-U涨1.48%,XD联影医、奕瑞科技、华大智造涨幅居前。从资金上来看,截止发稿,精准医疗概念主力净流入为-3413.72万,其中奕瑞科技受到资金热捧,主力净流入260.27万;拉长时间线来看,该板块近20日主力资金净流入-25.75亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718094059941f8108&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718094059941f8108&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688180"],"gpt_icon":0},{"id":"2452143080","title":"独家药品概念盘中拉升,君实生物-U涨1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452143080","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452143080?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:40","pubTimestamp":1721266802,"startTime":"0","endTime":"0","summary":"07月18日,独家药品概念盘中拉升,截至09点39分,独家药品概念整体指数上涨0.60%,报764.160点。从个股上来看,该概念的成分股中,君实生物-U涨1.48%,达仁堂、华润三九、同仁堂涨幅居前。从资金上来看,截止发稿,独家药品概念概念主力净流入为-2273.60万,其中同仁堂受到资金热捧,主力净流入140.49万;拉长时间线来看,该板块近20日主力资金净流入-29.02亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180940029681dd16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180940029681dd16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0113","BK0183","LU1688375341.USD","BK0012","BK0239","600085","BK0196","BK0028","688180","BK0188","BK0097","BK0086"],"gpt_icon":0},{"id":"2452162091","title":"君实生物(01877.HK)特瑞普利单抗新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452162091","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452162091?lang=zh_cn&edition=full","pubTime":"2024-07-18 00:49","pubTimestamp":1721234940,"startTime":"0","endTime":"0","summary":"君实生物(01877.HK) 公布,收到国家药品监督管理局通知,特瑞普利单抗(商品名:拓益,产品代号:JS001)联合贝伐珠单抗用于不可切除或转移性肝细胞癌患者的一线治疗的新适应症上市申请获得受理。本次新适应症上市申请主要基于HEPATORCH研究,结果显示,特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌患者,相较于索拉非尼,可显著延长患者的无进展生存期和总生存期,同时改善客观缓解率和至疾病进展时间等次要终点。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-17 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1364411/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0239","01877","688180","BK1583","BK1515","BK1161"],"gpt_icon":0},{"id":"2452156191","title":"君实生物(01877):特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452156191","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452156191?lang=zh_cn&edition=full","pubTime":"2024-07-17 20:33","pubTimestamp":1721219586,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 公布,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,特瑞普利单抗联合贝伐珠单抗用于不可切除或转移性肝细胞癌患者的一线治疗的新适应症上市申请获得受理。研究结果显示,特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌患者,相较于索拉非尼,可显著延长患者的 PFS 和 OS,同时改善客观缓解率和至疾病进展时间等次要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK0239","688180","01877","BK1583"],"gpt_icon":0},{"id":"2452134000","title":"君实生物:特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452134000","media":"国际金融报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452134000?lang=zh_cn&edition=full","pubTime":"2024-07-17 18:43","pubTimestamp":1721213008,"startTime":"0","endTime":"0","summary":"君实生物公告,特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717184337af92c301&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717184337af92c301&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK0239","688180"],"gpt_icon":0},{"id":"2451117953","title":"君实生物(01877)下跌5.13%,报12.58元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2451117953","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451117953?lang=zh_cn&edition=full","pubTime":"2024-07-16 14:28","pubTimestamp":1721111308,"startTime":"0","endTime":"0","summary":"7月16日,君实生物(01877)盘中下跌5.13%,截至14:28,报12.58元/股,成交937.54万元。上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法,特别是在肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。截至2024年一季报,君实生物营业总收入3.81亿元、净利润-2.83亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/16142841591216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK1583","BK0239","688180","BK1161","01877"],"gpt_icon":0},{"id":"2451953474","title":"君实生物盘中异动 下午盘快速跳水5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451953474","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451953474?lang=zh_cn&edition=full","pubTime":"2024-07-16 14:28","pubTimestamp":1721111305,"startTime":"0","endTime":"0","summary":"2024年07月16日下午盘14时28分,君实生物股票出现异动,股价快速跳水5.13%。截至发稿,该股报12.581港元/股,成交量72.4万股,换手率0.33%,振幅6.18%。君实生物股票所在的生物技术行业中,整体跌幅为0.12%。其相关个股中,维亚生物、亚盛医药-B、再鼎医药涨幅较大,振幅较大的相关个股有维亚生物、宜明昂科-B、圣诺医药-B,振幅分别为17.00%、16.14%、14.89%。药品批发,药品委托生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161428259681d1fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161428259681d1fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","01877","688180"],"gpt_icon":0},{"id":"2450803833","title":"君实生物(01877)上涨5.13%,报13.12元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450803833","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450803833?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:50","pubTimestamp":1720666206,"startTime":"0","endTime":"0","summary":"7月11日,君实生物(01877)盘中上涨5.13%,截至10:50,报13.12元/股,成交572.59万元。上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法,特别是在肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。截至2024年一季报,君实生物营业总收入3.81亿元、净利润-2.83亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/11105041505681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1161","BK0239","01877","BK1515","688180"],"gpt_icon":0},{"id":"2450808999","title":"君实生物盘中异动 急速上涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450808999","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450808999?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:49","pubTimestamp":1720666198,"startTime":"0","endTime":"0","summary":"2024年07月11日早盘10时49分,君实生物股票出现异动,股价急速上涨5.12%。截至发稿,该股报13.120港元/股,成交量44.38万股,换手率0.20%,振幅4.65%。君实生物股票所在的生物技术行业中,整体涨幅为1.58%。其相关个股中,北海康成-B、荣昌生物、盛禾生物-B涨幅较大,振幅较大的相关个股有北海康成-B、科伦博泰生物-B、盛禾生物-B,振幅分别为31.25%、19.37%、17.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407111049599681bdec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407111049599681bdec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK0239","688180"],"gpt_icon":0},{"id":"2450380335","title":"君实生物(01877)股价上升5.128%,现价港币$13.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2450380335","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450380335?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:49","pubTimestamp":1720666140,"startTime":"0","endTime":"0","summary":"[上升股]君实生物(01877) 股价在上午10:49比前收市价上升5.128%,现股价为港币$13.12。至目前为止,今日最高价为$13.12,而最低价为$12.54。总成交量为44.38万股,总成交金额为港币$572.586万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407112881/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01877","BK1515","688180","BK0239","BK1583","BK1161"],"gpt_icon":0},{"id":"2450709328","title":"君实生物-U创3月新高 11家券商给予买入建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2450709328","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450709328?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:23","pubTimestamp":1720664606,"startTime":"0","endTime":"0","summary":"07月11日,君实生物-U股价大幅上涨,截至10点23分,君实生物-U上涨5.09%,报31.58元/股,创近3月新高,成交8966万元,换手率0.38%,振幅4.39%。此外,数据统计显示,近半年内11家券商给予买入建议。北向资金方面,君实生物-U07月10日获得北向资金增持4.19万股,截至07月10日,北向资金当前共持有君实生物-U1005.56万股,市值3.18亿元,持股占流通股比为1.31%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711102427af91bc9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711102427af91bc9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688180"],"gpt_icon":0},{"id":"2450864003","title":"君实生物(01877)全资子公司苏州众合生物医药科技通过欧盟 GMP 认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2450864003","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450864003?lang=zh_cn&edition=full","pubTime":"2024-07-10 18:15","pubTimestamp":1720606544,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 公布,近日,公司全资子公司苏州众合生物医药科技有限公司收到爱尔兰健康产品监督管理局依据欧洲药品管理局相关法规颁发的《CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER》。本次系公司核心产品特瑞普利单抗注射液的相关生产设施首次通过欧盟成员国 GMP 认证。根据欧盟成员国之间的 GMP 互认制度,本次通过 GMP 认证表明本次接受认证的生产设施已符合欧盟 GMP 标准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1583","BK0239","688180","BK1161","161726","01877","399441"],"gpt_icon":0},{"id":"2450865483","title":"君实生物(688180.SH):子公司通过欧盟GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2450865483","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450865483?lang=zh_cn&edition=full","pubTime":"2024-07-10 17:14","pubTimestamp":1720602843,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物(688180.SH)发布公告,公司全资子公司苏州众合生物医药科技有限公司收到爱尔兰健康产品监督管理局依据欧洲药品管理局相关法规颁发的《药品GMP证书》。本次系公司核心产品特瑞普利单抗注射液的相关生产设施首次通过欧盟成员国GMP认证。根据欧盟成员国之间的GMP互认制度,本次通过GMP认证表明本次接受认证的生产设施已符合欧盟GMP标准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688180","BK1515","BK1583","BK0239","01877","BK1161"],"gpt_icon":0},{"id":"2450755075","title":"君实生物(01877.HK)WJ47156片临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2450755075","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450755075?lang=zh_cn&edition=full","pubTime":"2024-07-10 01:48","pubTimestamp":1720547280,"startTime":"0","endTime":"0","summary":"君实生物(01877.HK) 公布,收到国家药品监督管理局通知书,WJ47156片(项目代号JS125)的临床试验申请获得受理。JS125是靶向组蛋白去乙酰化酶抑制剂,由公司与微境生物医药科技(上海)合作开发,拟用于恶性肿瘤的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-09 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200529130906781_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200529130906781_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1362448/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0239","688180","BK1161","BK1141","01877","03347","BK1515","BK1576","BK1583"],"gpt_icon":0},{"id":"2450047443","title":"君实生物(01877):JS125 获得药物临床试验申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2450047443","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450047443?lang=zh_cn&edition=full","pubTime":"2024-07-09 21:18","pubTimestamp":1720531122,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 公布,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,WJ47156 片的临床试验申请获得受理。HDACs 具有多种亚型,JS125 可选择性对 HDAC1、HDAC2、HDAC3 产生抑制,并通过诱导细胞周期阻滞、抑制血管生成、调节免疫反应和促进癌症细胞衰老凋亡等来发挥抑制肿瘤作用,达到肿瘤治疗目的。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK0239","BK1141","688180","BK1583","BK1161","BK1515","BK1576","01877"],"gpt_icon":0},{"id":"2449471187","title":"概念掘金 | 创新药重磅政策落地!多主线投资机会显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2449471187","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449471187?lang=zh_cn&edition=full","pubTime":"2024-07-08 11:03","pubTimestamp":1720407822,"startTime":"0","endTime":"0","summary":"前景向好","market":"us","thumbnail":"https://img3.gelonghui.com/b2683-2091f5cb-365b-4f9a-b8c2-21c160148bbb.jpg?guru_height=852&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/b2683-2091f5cb-365b-4f9a-b8c2-21c160148bbb.jpg?guru_height=852&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/836139","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0239","600276","600867","BK0070","BK0185","BK1161","688488","LU1328615791.USD","BK0262","688506","LU0405327494.USD","LU1064130708.USD","LU2148510915.USD","BK0196","BK0060","BK0028","LU0405327148.USD","688180","BK0183","600521","BK1574","06978","BK0012","LU1064131003.USD","BK0201","BK0188"],"gpt_icon":0},{"id":"2449191322","title":"君实生物获得发明专利授权:“抗PD-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2449191322","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449191322?lang=zh_cn&edition=full","pubTime":"2024-07-06 03:09","pubTimestamp":1720206555,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示君实生物新获得一项发明专利授权,专利名为“抗PD-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法”,专利申请号为CN202180013449.X,授权日为2024年7月5日。具体而言,涉及抗PD1抗体和多受体酪氨酸激酶抑制剂的药物组合,以及其在制备用于预防或治疗癌症的药物中的用途及其使用方法。今年以来君实生物新获得专利授权6个,较去年同期增加了500%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070600003530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1161","BK0239","01877","BK1515","688180"],"gpt_icon":0},{"id":"2449235610","title":"君实生物(01877)上涨5.3%,报12.32元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449235610","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449235610?lang=zh_cn&edition=full","pubTime":"2024-07-05 13:55","pubTimestamp":1720158948,"startTime":"0","endTime":"0","summary":"7月5日,君实生物(01877)盘中上涨5.3%,截至13:55,报12.32元/股,成交608.41万元。上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法,特别是在肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。截至2024年一季报,君实生物营业总收入3.81亿元、净利润-2.83亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/05135541392352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1515","BK0239","688180","01877","BK1583"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-07-15","address":"上海市浦东新区中国(上海)自由贸易试验区海趣路36、58号2号楼10层1003室","stockEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.0963},{"period":"3month","weight":0.2908},{"period":"6month","weight":0.0022},{"period":"1year","weight":-0.1849},{"period":"ytd","weight":-0.235}],"companyName":"上海君实生物医药科技股份有限公司","boardCode":"AI0027","perCapita":"23654股","boardName":"医药制造业","registeredCapital":"98568万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":" 上海君实生物医药科技股份有限公司主营业务为新药的研发及相关技术的转让和服务,新药的生产和销售,其主要产品与服务项目单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术转让等。公司提供的技术服务指利用技术平台为客户提供定制服务,包括分子序列的设计及改造、高表达细胞株的构建、小试及中试工艺研究、临床前研究及临床研究样品的制备等。公司为第一家获得NMPA的抗PD-1单克隆抗体上市批准的中国公司。国内首个获批临床的抗PCSK9单抗、全球首个获批临床的抗BTLA单抗和首个在欧美等海外国家及地区获得紧急使用授权(EUA)的国产COVID-19治疗药物埃特司韦单抗。","serverTime":1721674756101,"listedPrice":55.5,"stockholders":"32322人(较上一季度减少2.07%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,688180,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}